MAP2K7 and colorectal carcinoma: These experiments suggested that the DDX3-KD-induced cell proliferation, migration and invasion are partially inhibited by the PD98059 MEK inhibitor and that targeting the MAPK pathway may be a treatment approach for advanced CRC.